Release of 6-KET0-PGF and thromboxane B2 in late appearing cardioprotection induced by the stable PGI analogue: 7-OXO-PGI

  • László Szekeres
  • Árpád Tósaki
Part of the Developments in Molecular and Cellular Biochemistry book series (DMCB, volume 9)

Abstract

We have shown earlier that prostacyclin (PGI2) and its stable analogue: 7-oxo-prostacyclin(7-OXO) may induce a prolonged, late appearing (24–48 h after drug administration), dose dependent protection of the heart from harmful consequences of a subsequent severe ischaemic stress, such as myocardial ischaemia, life-threatening ventricular arrhythmias and early ischaemic morphological changes. In an other study we observed that a similar but shortlived (less than 1 h) cardioprotection, induced by ‘preconditioning’ brief coronary artery occlusions, is greatly reduced by blockade of the cyclooxygenase pathway, suggesting that prostanoids might play a role in this shortlasting protection.

Objective of our present study was to elucidate the importance of some arachidonic acid (AA) metabolites, such as PGI2 and thromboxane A2 (TXA2) in the mechanism of the late appearing, prolonged cardioprotection. Estimation of the metabolites: 6-keto-PGF (6-KETO) and thromboxane B2 (TXB2) was made from the perfusate of isolated Langendorff hearts of guinea-pigs pretreated with 50μg/kg 7-OXO, 24 and 48 h before preparation. Pretreatment alone produced a slight, but significant elevation of 6-KETO (from 206 ± 11 to 284 ± 19 pg/ml/min after 24 h, and to 261 ± 18 pg/ml/min after 48 h). No change was seen in TXB2 production. Global ischaemia for 25 min (followed by 25 min reperfusion) markedly increased the release of both A A metabolites; maximal values were observed in the third min of reperfusion (6-KETO from 206 ± 11 to 1275 ± 55 pg/ml/min and TXB2 from 29 ± 4 to 172 ± 12pg/ml/min). All values returned to the preischaemic level by the 25th min of reperfusion. Ischaemic increase in 6-KETO level was significantly higher in the perfusate of hearts from pretreated animals (1507 ± 73 pg/ml/min after 24 h, and 1398 ± 54 pg/ml/min after 48 h) that in those of untreated controls. There was no difference in TXB2 values. Thus both basal and ischaemic release of PGI2 increased 24 and 48 h after pretreatment with 7-OXO but not TXA2 production. Results suggest that endogenous prostanoids might play a role in late appearing cardioprotection. (Mol Cell Biochem 119: 129–132, 1993)

Key words

late appearing cardioprotection PGI2 TXA2 ischaemia reperfusion 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Murry CE, Jennings RB, Reimer KA: Preconditioning with is-chaemia: A delay of lethal cell injury in ischaemic myocardium. Circulation 74: 1124–1136, 1986PubMedCrossRefGoogle Scholar
  2. 2.
    Komori S, Parratt JR, Szekeres L, Végh Á: Preconditioning reduces the severity of ischaemia and reperfusion-induced arrhythmias in both anaesthetized rats and dogs. J Physiol Lond 423: 16p, 1990Google Scholar
  3. 3.
    Végh Á, Komori S, Szekeres L, Parratt JR: Antiarrhythmic effects of preconditioning in anaesthetised dogs and rats. Cardio-vasc Res 26: 487–495, 1992CrossRefGoogle Scholar
  4. 4.
    Végh Á, Szekeres L, Parratt JR: Protective effects of preconditioning of the ischaemic myocardium involve cyclo-oxygenase products. Cardiovasc Res 24: 1020–1023, 1990PubMedCrossRefGoogle Scholar
  5. 5.
    Szekeres L, Krassói I, Udvary É: Delayed antiischaemic effect of Pgl2 and of a new stable Pgl2 analogue: 7-oxo-Prostacyclin-Na in experimental model angina in dogs. J Mol Cell Cardiol 15: Suppl I, 394, 1983Google Scholar
  6. 6.
    Szekeres L, Pataricza J, Szilvássy Z, Udvary É, Végh Á: Cardioprotection: Endogenous protective mechanism promoted by prostacyclin. In: RG Giilch, G Kissling (eds.) Current Topics in Heart Failure. Steinkopff Verl. Darmstadt. Basic Res Card 86: Suppl 3: 215–221, 1991Google Scholar
  7. 7.
    Coker SJ, Parratt JR, Ledingham IMcA, Zeitlin IJ: Thromboxane and prostacyclin release from ischaemic myocardium in relation to arrhythmias. Nature 291: 323–324, 1981PubMedCrossRefGoogle Scholar
  8. 8.
    Coker SJ, Parratt JR, Ledingham IMcA, Zeitlin IJ: Aspirin inhibits the early myocardial release of thromboxane B2 and ventricular ectopic activity following acute coronary artery occlusion in dogs. Br J Pharmacol 72: 593–595, 1981PubMedCrossRefGoogle Scholar
  9. 9.
    Coker SJ, Parratt JR: Effects of dazoxiben on arrhythmias and ventricular fibrillation induced by coronary artery occlusion and reperfusion in anaesthetised greyhounds. Br J Clin Pharmacol 15: 87–96, 1983CrossRefGoogle Scholar
  10. 10.
    Coker SJ, Parratt JR: The effects of nafazatrom on arrhythmias and prostanoid release during coronary artery occlusion and reperfusion in anaesthetised greyhounds. J Mol Cell Cardiol 16: 43–52, 1984PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1993

Authors and Affiliations

  • László Szekeres
    • 1
  • Árpád Tósaki
    • 2
    • 3
  1. 1.Institute of PharmacologyAlbert Szent-Györgyi Medical UniversitySzegedHungary
  2. 2.University of Connecticut Health CenterFarmingtonUSA
  3. 3.Institut Henry BeaufourLes UlisFrance

Personalised recommendations